The study results showed that senicapoc was well tolerated at all doses tested and in preliminary analyses exhibited predictable and dose proportional pharmacokinetics consistent with once-daily dosing. Additionally, there were no dose-limiting toxicities in any subject.
The company expects to initiate a Phase II proof-of-concept clinical trial in asthma during the second half of 2008. The initial Phase II proof-of-concept study is expected to be conducted in patients with allergen induced asthma.
The company expects to enroll approximately subjects in a short-duration study to examine the effect of senicapoc upon certain pulmonary function parameters following exposure of asthmatic patients to a known antigen. The study will be conducted at selected sites in the UK.